Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer
Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer
The purpose of this study is to determine if Prostate-Specific Membrane Antigen (PSMA)
 positron emission tomography (PET) scans used in this study accurate and better at imaging
 participants' prostate cancer than the usual methods.
Inclusion Criteria:

 -  Patients with histologically confirmed prostate cancer, that is either: newly
 diagnosed OR progressive as defined by standard PCWG3 criteria. note that metastatic
 disease is defined by either bone scintigraphy or by CT or MRI, or a combination of
 these tests, but not exclusively by molecular imaging criteria.

 Patients with newly diagnosed localized or metastatic prostate cancer are eligible,
 provided standard imaging (either bone scintigraphy, CT or MRI) demonstrates evidence of
 radiographic disease

 Patient with progressive disease that is non-metastatic are eligible by biochemical
 progression: A minimum of three rising PSA values from a baseline that are obtained 1 week
 or more apart, or 2 measurements 2 or more weeks apart

 Patients with progressive disease that is metastatic are eligible either by biochemical
 progression or radiographic progression or both

 Patients are permitted to have had up to 2 months of prior hormonal therapy before entering
 this trial (and many therapeutic trials) and therefore, their progression criteria would
 apply to their pre-treatment imaging and PSA parameters

 -  Karnofsky performance status of >/= 50 (or ECOG/WHO equivalent)

 -  Male (or transgender female) > 18 years of age

 -  Patient must be able to understand and willing to sign a written informed consent
 document

 -  Patient is anticipating starting a therapeutic strategy following imaging

 Exclusion Criteria:

 -  Patient undergoing active treatment for non-prostate malignancy, other than skin basal
 cell or cutaneous superficial squamous cell carcinoma that has not metastasized and
 non-invasive bladder cancer

 -  Unable to lie flat, still or tolerate a PET scan